731 results on '"Lindstedt, Malin"'
Search Results
2. Pattern recognition receptor expression and maturation profile of dendritic cell subtypes in human tonsils and lymph nodes
3. An integrated transcriptomic- and proteomic-based approach to evaluate the human skin sensitization potential of glyphosate and its commercial agrochemical formulations
4. The 21st Century movement within the area of skin sensitization assessment: From the animal context towards current human-relevant in vitro solutions
5. Targeted spatial proteomic analysis of CD8+ T- and myeloid cells in tonsillar cancer
6. 837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro
7. Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
8. 2026 – A CANCER IMMUNOTHERAPY MODALITY BASED ON DENDRITIC CELL REPROGRAMMING IN VIVO
9. GARD: Genomic Allergen Rapid Detection
10. Predicting skin sensitizers with confidence — Using conformal prediction to determine applicability domain of GARD
11. An alternative biomarker-based approach for the prediction of proteins known to sensitize the respiratory tract
12. Restoring tumor immunogenicity with dendritic cell reprogramming
13. Next-generation CD40 agonists for cancer immunotherapy
14. Targeted spatial proteomic analysis of CD8+ T- and myeloid cells in tonsillar cancer.
15. From genome-wide arrays to tailor-made biomarker readout – Progress towards routine analysis of skin sensitizing chemicals with GARD
16. Exploring Spatial Heterogeneity of Immune Cells in Nasopharyngeal Cancer
17. Abstract 2939: ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo
18. Supplementary Figure 1 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
19. Supplementary Methods from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
20. Supplementary Tables from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
21. Supplementary Figure 6 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
22. Supplementary Figure 5 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
23. Supplementary Figure 4 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
24. Restoring tumor immunogenicity with dendritic cell reprogramming
25. Nanoparticle-Based Specific Targeting of Antigen-Presenting Cells for Immunotherapy
26. Intralesional EBV-DNA load as marker of prognosis for nasopharyngeal cancer
27. A proteomics dataset capturing myeloid cell responses upon cellular exposure to fungicides, adjuvants and fungicide formulations
28. Single-cell analysis of myeloid cells in HPV+ tonsillar cancer
29. Upper airway microbiome transplantation for patients with chronic rhinosinusitis
30. Systematic evaluation of non-animal test methods for skin sensitisation safety assessment
31. Abstract A40: Restoring tumor immunogenicity with dendritic cell reprogramming
32. 35 Early pharmacodynamic changes measured by RNA sequencing in peripheral blood from patients in a phase 1 study with mitazalimab, a potent CD40 agonistic IgG1 monoclonal antibody
33. 102 Exploring the spatial heterogeneity of immune cells in nasopharyngeal tumours
34. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
35. Single-cell analysis of myeloid cells in HPV+tonsillar cancer
36. Profiling dendritic cell subsets in head and neck squamous cell tonsillar cancer and benign tonsils
37. The GARD assay for assessment of chemical skin sensitizers
38. Allergy
39. Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles
40. Nasal administration of a probiotic assemblage in allergic rhinitis: A randomised placebo‐controlled crossover trial
41. Tonsillar Cancer with High CD8+ T-Cell Infiltration Features Increased Levels of Dendritic Cells and Transcriptional Regulation Associated with an Inflamed Tumor Microenvironment
42. Single-cell analysis of myeloid cells in HPV+ tonsillar cancer.
43. In vivo dendritic cell reprogramming for cancer immunotherapy.
44. Reprogramming Human Cancer Cells into Antigen Presentation
45. Immune delineation of laryngeal papilloma reveals enhanced neutrophil associated gene profile
46. Immune delineation of laryngeal papilloma reveals enhanced neutrophil associated gene profile
47. Prediction of Skin Sensitizers using Alternative Methods to Animal Experimentation
48. Circulating CD1c+ DCs are superior at activating Th2 responses upon Phl p stimulation compared with basophils and pDCs
49. Safe cosmetics without animal testing? Contributions of the EU Project Sens-it-iv
50. Genomic Allergen Rapid Detection In-House Validation—A Proof of Concept
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.